Revolution Medicines
Clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. Publicly traded on NASDAQ (RVMD), focused on RAS(ON) and RAS Companion inhibitors.
Notes
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is publicly traded on NASDAQ under the ticker symbol RVMD.
RAS mutations are among the most common oncogenic drivers in human cancers, found in approximately 25-30% of all cancers. Revolution Medicines is developing a portfolio of RAS(ON) inhibitors that directly target RAS in its active, "ON" state, as well as RAS Companion inhibitors that work synergistically with RAS(ON) inhibitors.
The company's lead programs target KRAS mutations, which are particularly prevalent in pancreatic, colorectal, and lung cancers.
Team
- Mark A. Goldsmith, M.D., Ph.D. - Chief Executive Officer & Co-founder
- LinkedIn: linkedin.com/in/mark-goldsmith
- Jack Anders - President
- Jorge DiMartino, M.D., Ph.D. - Chief Medical Officer
- Erin Lavelle - Chief Financial Officer
- Kevan Shokat, Ph.D. - Co-founder, Scientific Advisory Board
Additional Research Findings
- NASDAQ: RVMD (publicly traded)
- Founded in 2014
- Focus on RAS-addicted cancers (KRAS mutations)
- RAS(ON) inhibitor platform
- RAS Companion inhibitors for combination therapy
- Targeting pancreatic, colorectal, and lung cancers
- Headquarters in Redwood City, California
- Multiple clinical-stage programs